Current Role of Anti-Angiogenic Strategies for Glioblastoma

Current Treatment Options in Oncology

Volumn 15, Issue 4, 2014, Pages 551-566

  Thomas, Alissa A ^b   Omuro, Antonio ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Angiogenesis; Bevacizumab; Glioblastoma; Treatment; Vascular endothelial growth factor (VEGF)

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BORTEZOMIB; CARMUSTINE; CEDIRANIB; CILENGITIDE; CORTICOSTEROID; CRIZOTINIB; DASATINIB; ENZASTAURIN; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; IRINOTECAN; LOMUSTINE; NELFINAVIR; PLACEBO; PLERIXAFOR; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TRC 105; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ADJUVANT CHEMORADIOTHERAPY; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL PERMEABILITY; BRAIN EDEMA; CANCER RECURRENCE; CANCER RESISTANCE; CONTRAST ENHANCEMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOBLASTOMA; HEALTH CARE COST; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CARCINOMA; METASTATIC COLORECTAL CANCER; NEUROIMAGING; NEUROLOGIC DISEASE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; BRAIN NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 84919932068     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0308-2     Document Type: Review

References (59)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
2. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl). 2007;114:97–109.
4. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845–8.
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.
6. Schmidt NO, Westphal M, Hagel C, Ergun S, Stavrou D, Rosen EM, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999;84:10–8.
7. Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Investig. 1992;67:529–34.
8. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg. 1995;82:864–73.
9. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4:121–33.
10. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8:604–17.
11. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005;7:122–33.
12. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998;153:1459–66.
13. Reynes G, Vila V, Martin M, Parada A, Fleitas T, Reganon E, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol. 2011;102:35–41.
14. Hemmerle T, Neri D. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer. 2014;134:467–77.
15. De Bouard S, Guillamo JS, Christov C, Lefevre N, Brugieres P, Gola E, et al. Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatin. Hum Gene Ther. 2003;14:883–95.
16. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W, et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol. 2011;13:99–108.
17. Weathers SP, de Groot J. Resistance to antiangiogenic therapy. Curr Neurol Neurosci Rep. 2014;14:443.
18. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468:829–33.
19. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neurooncology. 2005;7(3):369. Meeting Abstracts.
20. Vredenburgh JJ, Desjardins A, Herndon II JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–9.
21. Vredenburgh JJ, Desjardins A, Herndon II JE, Dowell JM, Reardon D, Quinn J, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Clin Cancer Res. 2007;13:1253–9.
22. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131–8.
23. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.
24. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.
25. Bazzoli E, Omuro AM. Antiangiogenic strategies for the treatment of gliomas. In: Ray SK, editor. Glioblastoma: molecular mechanisms of pathogenesis and current therapeutic strategies. New York: Springer; 2010. p. 243–64.
26. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon II JE, Marcello J, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17:4119–24.
27. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142–8.
28. Omuro A, Beal K, Karimi S, Chan T, Panageas K, Nayak L, et al. Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). J Clin Oncol. 2010;28(15 Suppl):2036. Meeting Abstracts.
29. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22. Landmark trial investigating bevacizumab for newly diagnosed glioblastoma.
30. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708. Companion article to Chinot et al above. Also a landmark trial for bevacizumab in newly diagnosed glioblastoma.
31. Taal W, Oosterkamp HM, Walenkamp AME, Beerepoot LV, Hanse M, Buter J, et al. A randomized phase II study of bevacizumab vs bevacizumab plus lomustine vs lomustine single agent in recurrent glioblastoma: the Dutch BELOB study. J Clin Oncol. 2013;31(Suppl): [Abstract 2001].
32. Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger. Ann Oncol. 2014;25:1442–7.
33. Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2013;2:185–95.
34. Sathornsumetee S, Cao Y, Marcello JE, Herndon II JE, McLendon RE, Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol. 2008;26:271–8.
35. Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, et al. Phase II study of bevacizumab, temozolomide and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical Cancer Research. 2014. doi: 10.1158/1078-0432
36. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73.
37. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
38. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4:e7752.
39. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–77.
40. Phillips H, Sandmann T, Li C, Cloughesy TF, Chinot OL, Wick W, et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB]). ASCO Meet Abstr. 2014;32(15 Suppl):2001.
41. Daras M, Abrey L, Sanchez J, Beal K, Gutin P, Kaley T, et al. RA-013. Diffusion and perfusion magnetic resonance imaging in newly diagnosed glioblastoma following treatment with bevacizumab, temozolomide and hypo-fractionated stereotactic radiotherapy. Neurooncology. 2013;15 Suppl 3:iii191–205.
42. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. Am J Neuroradiol. 2011;32:882–9.
43. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013;110:19059–64.
44. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18 F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21.
45. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83–95.
46. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75:156–63.
47. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79:1487–95.
48. Jeyaretna DS, Curry Jr WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011;29:e159–62.
49. Thomas AA, BC, DeAngelis LM, Omuro AM. Emerging therapies for glioblastoma. JAMA Neurology. 2014:[Pub pending].
50. Hutterer M, Nowosielski M, Haybaeck J, Embacher S, Stockhammer F, Gotwald T, et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neurooncology. 2014;16:92–102.
51. Kreisl TN, McNeill KA, Sul J, Iwamoto FM, Shih J, Fine HA. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neurooncology. 2012;14:1519–26.
52. Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer. 2010;46:348–54.
53. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, vs lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31:3212–8.
54. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29:2689–95.
55. Stupp R HM, Gorlia T, Erridge S, Grujicic D, Steinbach JP, Wick W, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. J Clin Oncol. 2013;31(Suppl l):LBA2009.
56. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L, et al. Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol. 2010;99:237–42.
57. Reardon DA, Herndon II JE, Peters KB, Desjardins A, Coan A, Lou E, et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer. 2012;107:1481–7.
58. Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neurooncology. 2013;15:242–50.
59. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001;61:7846–54.